3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
76
Gynecologic
4
Tumor-Agnostic
2
Genitourinary
2
Gastrointestinal
2
Endocrine
2
Other
1
NET
1
Head & Neck
1
Conditions
Uterine Cervical Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Ovarian Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Hereditary Sensory and Autonomic Neuropathies
1
Head and Neck Neoplasms
1
Endometrial Neoplasms
1
Breast Neoplasms
1
Breast Diseases
1
Interventions
pembrolizumab
180
Cisplatin
157
Radiotherapy
78
Carboplatin
71
Radiotherapy, Intensity-Modulated
69
Cetuximab
66
Magnetic Resonance Spectroscopy
64
Nivolumab
63
Paclitaxel
52
Docetaxel
50
Specimen Handling
45
Radiation
35
Gemcitabine
33
Fluorouracil
31
Surveys and Questionnaires
28
Biopsy
27
toripalimab
26
Drug Therapy
26
Platinum
25
Surgical Procedures, Operative
24
Standard of Care
23
1,2-diaminocyclohexaneplatinum II citrate
23
cemiplimab
22
atezolizumab
21
Capecitabine
20
Ipilimumab
19
Chemoradiotherapy
19
durvalumab
18
Taxes
17
Immune Checkpoint Inhibitors
17
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
exemestane
×
Head & Neck
×
1 year
×
Clear all
NCT05768139
2026-06-04
PIKALO-1
Eli Lilly and Company
Phase 1/2
Recruiting
880 enrolled